Key Points
- Scott Gottlieb, an Illumina director, purchased 200 shares on Feb. 9 at an average price of $117.81 (total $23,562), raising his stake to 12,723 shares (a 1.6% increase); the transaction was disclosed on an SEC Form 4.
- Illumina reported an EPS beat for the quarter ($1.35 vs. $1.26 expected) and revenue of $1.16B (vs. $1.10B expected), and set FY2026 guidance of 5.050–5.200 EPS.
- The stock carries an average analyst rating of "Hold" with a $129.17 average price target, and institutional investors own 89.42% of shares, with several large funds markedly increasing their stakes recently.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Scott Gottlieb acquired 200 shares of the stock in a transaction on Monday, February 9th. The shares were acquired at an average cost of $117.81 per share, for a total transaction of $23,562.00. Following the completion of the transaction, the director directly owned 12,723 shares in the company, valued at $1,498,896.63. The trade was a 1.60% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Illumina Price Performance
Shares of ILMN opened at $116.38 on Thursday. The company has a market capitalization of $17.78 billion, a price-to-earnings ratio of 21.35, a price-to-earnings-growth ratio of 2.28 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The firm has a 50-day simple moving average of $137.81 and a 200-day simple moving average of $116.48. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.10 billion. During the same period last year, the firm earned $0.95 EPS. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.
Institutional Trading of Illumina
Several large investors have recently bought and sold shares of the company. Capital World Investors lifted its stake in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company's stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the period. AQR Capital Management LLC lifted its stake in shares of Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company's stock worth $313,290,000 after purchasing an additional 1,174,295 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company's stock worth $124,145,000 after purchasing an additional 911,843 shares during the last quarter. Edmond DE Rothschild Holding S.A. grew its position in shares of Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company's stock valued at $136,312,000 after purchasing an additional 833,750 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in Illumina by 1,558.0% in the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company's stock valued at $69,528,000 after purchasing an additional 684,802 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Illumina in a report on Monday, December 29th. UBS Group reaffirmed a "neutral" rating and issued a $135.00 price objective on shares of Illumina in a report on Friday, February 6th. Evercore set a $150.00 target price on Illumina in a research report on Friday, February 6th. Robert W. Baird set a $137.00 price target on Illumina in a report on Friday, February 6th. Finally, Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $150.00 and gave the company a "hold" rating in a research note on Monday, January 26th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $129.17.
Read Our Latest Stock Report on Illumina
About Illumina
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
